Clinical Trials Browser

Blood Protein Disorders, Cardiovascular Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Lymphoid, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Recurrence, Vascular Diseases, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Hemostatic Disorders, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell, Dendritic Cell Sarcoma, Interdigitating

NCT04191616 2025-09-04

SELECT

Phase 2 Completed

54 enrolled 17 charts

Plasma cell

Multiple Myeloma, Recurrence

NCT05565807 2025-08-15

Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma

Phase 1/2 Recruiting

84 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT02899052 2025-08-05

Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

Phase 2 Active not recruiting

120 enrolled

Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT06163040 2025-07-31

A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan

Completed

7 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT05011097 2025-07-20

A Phase I Clinical Trial of Y150 in the Treatment of Relapsed or Refractory Multiple Myeloma

Phase 1 Completed

20 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT06055075 2025-07-14

A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Completed

19 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT03539744 2025-06-19

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

Phase 3 Active not recruiting

265 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Recurrence

NCT05463939 2025-06-15

Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients

Approved for marketing

Plasma cell

Multiple Myeloma, Recurrence

NCT03361748 2025-05-23

KarMMa

Phase 2 Completed

149 enrolled 29 charts 1 FDA

Plasma cell

Multiple Myeloma, Recurrence

NCT04176380 2025-05-15

RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma

Phase 2 Completed

15 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT05673967 2025-04-25

Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma

Completed

62 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT03486067 2025-04-17

Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma

Phase 1 Terminated

183 enrolled

Plasma cell

Multiple Myeloma, Recurrence

Clinical Trials

SUCCESSOR-2

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

MajesTEC-10

A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma

SUCCESSOR-1

Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

KarMMa-2

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

LINKER-MM1

Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma

MagnetisMM-9

QUINTESSENTIAL

MagnetisMM-30

A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma

Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma

MagnetisMM-20

DREAMM-20

MonumenTAL-3

A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

STOMP

GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies

Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma

DREAMM 13

DC15-MM-01

Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM)

INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma

DREAMM 14

Non Interventional Study to Investigate the Safety and Effectiveness in Patients With Relapsed and Refractory Multiple Myeloma Treated With Elranatamab Under the Actual Use.

LINKER-AL2

A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma

A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies

Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

ARQ 531-101

SELECT

Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma

Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan

A Phase I Clinical Trial of Y150 in the Treatment of Relapsed or Refractory Multiple Myeloma

A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients

KarMMa

RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma

Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma

Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma